Turning cold tumors into hot tumors by improving T-cell infiltration.

Liu YT, Sun ZJ. · 2021

Read Turning cold tumors into hot tumors by improving T-cell infiltration. by Liu YT, Sun ZJ. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8039952.txt.

Introduction

Liu and Sun review how to turn cold tumors into hot ones by drawing in T cells. Immune checkpoint inhibitors have reshaped cancer care. Their power depends on T cells that enter the tumor and kill its cells. Cold tumors lack that infiltration, so the drugs fail there. Hot tumors, rich in T cells, respond far better.

The review explains why tumors stay cold. Faulty T-cell priming and weak homing signals share the blame. The authors then collect the strategies that heat tumors up. Each works by raising priming, guiding T cells in, or both. Nanomaterials earn a closing section of their own. Paired with immunotherapy, they sharpen antigen display and T-cell entry. Combination treatments built on these ideas may widen who benefits.

Catalog record

CREATORLiu YT, Sun ZJ.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE97 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8039952

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Turning cold tumors into hot tumors by improving T-cell infiltration By Yuan-Tong Liu, Zhi-Jun Sun Published in: Theranostics DOI: 10.7150/thno.58390 ABSTRACT Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has greatly improved the clinical efficacy of malignant tumor therapy. ICI-mediated antitumor responses depend on the infiltration of T cells capable of recognizing and killing tumor cells. ICIs are not effective in "cold tumors", which are characterized by the lack of T-cell infiltration. To realize the full potential of immunotherapy and solve this obstacle, it is essential to understand the drivers of T-cell infiltration into tumors. We present a critical review of our understanding of the mechanisms underlying “cold tumors”, including impaired T-cell priming and deficient T-cell homing to tumor beds. “Hot tumors” with significant T-cell infiltration are associated with better ICI efficacy. In this review, we summarize multiple strategies that promote the transformation of "cold tumors" into “hot tumors” and discuss the mechanisms by which these strategies lead to increased T-cell infiltration. Finally, we discuss the application of nanomaterials to tumor immunotherapy and provide an outlook on the future of this emerging field. The combination of nanomedicines and immunotherapy enhances cross-presentation of tumor antigens and promotes T-cell priming and infiltration. A deeper understanding of these mechanisms opens new possibilities for the development of multiple T cell-based combination therapies to improve ICI effectiveness. INTRODUCTION Recently, immune checkpoint inhibitors (ICIs), such as nivolumab and pembrolizumab, have been applied to an increasing number of cancer types, forming a paradigm treatment in clinical trials 1, 2. Although ICIs have shown clinical activity in a wide range of tumor types, a substantial percentage of patients still do not respond to ICI therapy 3. ICI-mediated antitumor responses rely on the expression of PD-L1 in tumors and the infiltration of T cells capable of recognizing and killing tumor cells. Immune cells such as CD8+ T cells are associated with prolonged survival of cancer patients and increased efficacy of immunotherapy 4. A lack of T cells in tumors can lead to resistance to immunotherapy 5. The success of chimeric antigen receptor (CAR) T-cell infusions for patients' leukemia and lymphoma also demonstrates the importance of T cells in antitumor immunity 6. Considering the potential mechanisms of cancer immunotherapy, the infiltration of CD8+ T lymphocytes in tumors is important for the therapeutic response to ICIs. According to the spatial distribution of cytotoxic immune cells in the tumor microenvironment (TME), a tumor is classified into one of three basic immunophenotypes: immune-inflamed, immune-excluded and immune-desert phenotypes (Figure 1) 3. Immune-inflamed tumors, also named “hot tumors”, are characterized by high T-cell infiltration, increased interferon-γ (IFN-γ) signaling, expression of PD-L1 and high tumor mutational burden (TMB) 7. Tumors with an inflamed phenotype tend to be more responsive to ICIs 8, 9. Immune-excluded tumors and immune-desert tumors can be described as “cold tumors”. In immune-excluded tumors, CD8+ T lymphocytes localize only at invasion margins and do not efficiently infiltrate the tumor 10. In immune-desert tumors, CD8+ T lymphocytes are absent from the tumor and its periphery 10. In addition to poor T-cell infiltration, “cold tumors” are characterized by low mutational load, low major histocompatibility complex (MHC) class I expression and low PD-L1 expression 7. Immunosuppressive cell populations, including tumor-associated macrophages (TAMs) and T-regulatory cells (Tregs) and myeloid-derived suppressor cells (MDSCs), are also present in cold tumors 7. These features suggest that cold tumors lack innate immunity or that the innate antitumor immune features present in “cold tumors” may be ineffective due to the exclusion of immune cells 3. In contrast to the inflamed phenotype, cold tumors rarely respond to ICI monotherapy 9. Driving T cells into the TME is a gradual process (Figure 2): tumor cell death and antigen release, antigen-presenting cell (APC) processing and presentation of tumor antigens, and APC and T-cell interactions lead to T-cell priming and activation 11. Ideally, once activated, these tumor-specific T cells exit lymph nodes and travel through the bloodstream to tumor site 11. The production of T cells and their physical contact with tumor cells is crucial for the success of antitumor immunity 12. Once infiltrating the tumor bed, cytotoxic T lymphocytes (CTLs) specifically recognize antigenic peptide-MHC complexes on the surface of tumor cells, form immune synapses, and release perforin and granzyme to destroy the tumor cells 13. In addition, CTLs contribute to the apoptosis of tumor cells through the Fas/FasL pathway and suppress tumors by inducing ferroptosis and pyroptosis 14. Dead tumor cells release additional tumor antigens and thereby amplify the T-cell response 11. With the development of nanotechnology, immunotherapy based on nanomedicines and biomaterials offers new opportunities for the future. Nanomedicines offer unique advantages in oncology treatment, such as improved drug precision and bioavailability and reduced immunotherapy-induced side effects 15. In addition, nanomedicines promote selective accumulation in tumors through enhanced permeability and retention (EPR) effects or include high-affinity ligands to achieve active targeting of tumors 15. Nanotechnology-based immunotherapy enhances tumor-specific immune responses, promotes the infiltration of CTLs, and inhibits tumor metastasis and recurrence. Given the importance of T-cell infiltration, understanding the mechanisms of T-cell homing to the tumor is necessary. To improve the clinical benefit of immunotherapy, ICIs may be combined with strategies that convert “cold tumors” to “hot tumors”, which may make these tumors more sensitive to ICI therapy. In this review, we summarize the various mechanisms of T-cell infiltration disorders and current approaches to directing T cells into tumors. Finally, we summarize recent advances, challenges and opportunities for nanomedicine-based local therapeutic strategies to enhance T-cell infiltration and discuss further prospects in this field. MECHANISMS OF THE “COLD TUMOR” PHENOTYPE ICI response rates are low in “cold tumors”, as characterized by the absence of T-cell infiltration. In the process of driving T cells into tumors, there are many factors that can influence T-cell priming and T-cell homing to the tumor bed, leading to a noninflamed T-cell phenotype and failed antitumor immunity (Figure 3). DEFECTIVE T-CELL PRIMING Lack of tumor antigens The most direct cause of T-cell priming disorders is insufficient T-cell recognition due to a lack of tumor antigens. Table 1 summarizes the mechanisms of defects in T-cell priming. In general, targeted tumor antigens can be classified into two broad categories: nonmutated self-antigens and neoantigens generated by nonsynonymous somatic mutations 16. Self-antigens include nonmutated proteins that are aberrantly expressed or overexpressed in tumor cells, such as tumor-associated antigens (TAAs) and cancer/testis antigens (CTAs). Although self-antigens also elicit a tumor immune response, the primary target of the immune response is neoantigens, also termed tumor-specific antigens (TSAs). Neoantigens are specific to tumor cells and arise from somatic mutations in cancer genomes 16. The recognition of tumor neoantigens may promote T-cell priming and infiltration and can lead to a long-term clinical response 11, 16. The TMB is broadly characterized as the number of total nonsynonymous single-nucleotide mutations in a tumor. In general, tumors with a higher TMB are believed to carry a higher neoantigen load that can be recognized by T cells, making them more likely to prime the immune system 17. Significant associations between high TMB and improved response to ICIs have been reported in a variety of tumor types 18, 19. The TMB has been used as a novel biomarker to predict the efficacy of programmed cell

Read the complete text